<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36780064</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1655</StartPage><EndPage>1664</EndPage><MedlinePgn>1655-1664</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06533-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">At present, the treat-to-target approach has been proposed with the lupus low disease activity state (LLDAS) as an achievable target.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine damage accrual and baseline clinical characteristics associated with achieving LLDAS within 12&#xa0;months of treatment in patients with childhood-onset systemic lupus erythematosus (c-SLE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study was conducted at the largest university-based tertiary referral center in Thailand. Data of c-SLE patients (&#x2264;&#x2009;18&#xa0;years) at diagnosis who were followed&#x2009;&#x2265;&#x2009;12&#xa0;months during January 2009 to December 2019 were collected. SLE disease status was categorized into LLDAS and non-optimally controlled state. SLEDAI-2K score was used to assess disease activity. Damage accrual was assessed by a pediatric version of the SLICC/ACR damage index.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 232 c-SLE patients (85.8% female) were included. At 12&#xa0;months of treatment, 109 (47%) patients achieved LLDAS. Damage accrual was observed in 93 (40.1%) patients at the mean follow-up time of 6.2&#x2009;&#xb1;&#x2009;3.7&#xa0;years. Damage accrual was significantly lower in patients who achieved LLDAS within 12&#xa0;months than in those non-optimally controlled (p&#x2009;=&#x2009;0.002). The median time to achieving LLDAS was 12.6&#xa0;months (95%CI: 11.19-13.97). The median time to achieving LLDAS was significantly shorter in those without renal involvement (10.8&#xa0;months, 95%CI: 9.62-12.00 vs. 15.6&#xa0;months, 95%CI: 13.76-17.52, respectively; p&#x2009;=&#x2009;0.044). Multivariable logistic regression analysis revealed absence of renal involvement as the predictor of achieving LLDAS within 12&#xa0;months of treatment (aOR: 2.430, 95%CI: 1.420-4.158; p&#x2009;=&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Achieving LLDAS within 12&#xa0;months of treatment was associated with lower damage accrual. Absence of renal involvement was the predictor of achieving LLDAS within 12&#xa0;months of treatment. Key Points &#x2022; LLDAS is a promising and achievable treatment target in c-SLE. &#x2022; Achieving LLDAS within 12 months of treatment is associated with lower damage accrual. &#x2022; Absence of renal involvement is the predictor of achieving LLDAS within 12 months of treatment.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Na Nakorn</LastName><ForeName>Koravich</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piyaphanee</LastName><ForeName>Nuntawan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sukharomana</LastName><ForeName>Maynart</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinpatanapong</LastName><ForeName>Rattakorn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charuvanij</LastName><ForeName>Sirirat</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0506-6039</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. sirirat.chv@mahidol.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N" Type="Geographic">Thailand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Childhood-onset systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">LLDAS</Keyword><Keyword MajorTopicYN="N">Lupus low disease activity state</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>13</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36780064</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06533-8</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06533-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aggarwal A, Srivastava P (2015) Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis 18:182&#x2013;191. https://doi.org/10.1111/1756-185X.12419</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12419</ArticleId><ArticleId IdType="pubmed">24965742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis S, Silverman ED (2010) Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 6:538&#x2013;546. https://doi.org/10.1038/nrrheum.2010.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.121</ArticleId><ArticleId IdType="pubmed">20683438</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Phatak S, Srivastava P, Lawrence A, Agarwal V, Misra R (2018) Outcomes in juvenile onset lupus: single center cohort from a developing country. Lupus 27:1867&#x2013;1875. https://doi.org/10.1177/0961203318791046</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318791046</ArticleId><ArticleId IdType="pubmed">30071768</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM (2017) Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 76:2009&#x2013;2016. https://doi.org/10.1136/annrheumdis-2017-211663</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Tektonidou MG (2020) Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatol (Oxford) 59:v29&#x2013;v38. https://doi.org/10.1093/rheumatology/keaa382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim LSH, Pullenayegum E, Lim L, Gladman D, Feldman B, Silverman E (2017) From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 69:1627&#x2013;1635. https://doi.org/10.1002/acr.23199</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23199</ArticleId><ArticleId IdType="pubmed">28118527</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R et al (2006) A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54:2989&#x2013;2996. https://doi.org/10.1002/art.22048</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22048</ArticleId><ArticleId IdType="pubmed">16947634</ArticleId></ArticleIdList></Reference><Reference><Citation>Salah S, Lotfy HM, Mokbel AN, Kaddah AM, Fahmy N (2011) Damage index in childhood-onset systemic lupus erythematosus in Egypt. Pediatr Rheumatol Online J 9:36. https://doi.org/10.1186/1546-0096-9-36</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1546-0096-9-36</ArticleId><ArticleId IdType="pubmed">22152340</ArticleId><ArticleId IdType="pmc">3261107</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato JO, Corrente JE, Saad-Magalhaes C (2015) Chronic active disease pattern predicts early damage in juvenile systemic lupus erythematosus. Lupus 24:1421&#x2013;1428. https://doi.org/10.1177/0961203315599449</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315599449</ArticleId><ArticleId IdType="pubmed">26253073</ArticleId></ArticleIdList></Reference><Reference><Citation>Artim-Esen B, Sahin S, Cene E, Sahinkaya Y, Barut K, Adrovic A et al (2017) Comparison of disease characteristics, organ damage, and survival in patients with juvenile-onset and adult-onset systemic lupus erythematosus in a combined cohort from 2 tertiary centers in Turkey. J Rheumatol 44:619&#x2013;625. https://doi.org/10.3899/jrheum.160340</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.160340</ArticleId><ArticleId IdType="pubmed">28298568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sit JKK, Chan WKY (2018) Risk factors for damage in childhood-onset systemic lupus erythematosus in Asians: a case control study. Pediatr Rheumatol Online J 16:56. https://doi.org/10.1186/s12969-018-0271-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-018-0271-8</ArticleId><ArticleId IdType="pubmed">30201026</ArticleId><ArticleId IdType="pmc">6131800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED (2008) Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152:550&#x2013;556. https://doi.org/10.1016/j.jpeds.2007.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2007.09.019</ArticleId><ArticleId IdType="pubmed">18346514</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanigava NY, Sakamoto AP, Franco AS, Balbi GG, Sales LP, Aikawa NE et al (2022) Social impact of disease parameters and damage accrual in adult Brazilian patients with childhood-onset systemic lupus erythematosus. Lupus 31:944&#x2013;952. https://doi.org/10.1177/09612033221097798</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221097798</ArticleId><ArticleId IdType="pubmed">35467441</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Hedrich CM (2022) Systemic lupus erythematosus - are children miniature adults? Clin Immunol 234:108907. https://doi.org/10.1016/j.clim.2021.108907</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108907</ArticleId><ArticleId IdType="pubmed">34890808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M et al (2010) Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19:949&#x2013;956. https://doi.org/10.1177/0961203310366572</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310366572</ArticleId><ArticleId IdType="pubmed">20375124</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Magder LS (2018) Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol 70:1790&#x2013;1795. https://doi.org/10.1002/art.40571</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40571</ArticleId><ArticleId IdType="pubmed">29806142</ArticleId><ArticleId IdType="pmc">6203602</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958&#x2013;967. https://doi.org/10.1136/annrheumdis-2013-205139</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L et al (2016) Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 75:1615&#x2013;1621. https://doi.org/10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A et al (2017) Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 19:247. https://doi.org/10.1186/s13075-017-1451-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1451-5</ArticleId><ArticleId IdType="pubmed">29126432</ArticleId><ArticleId IdType="pmc">5681839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A et al (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77:104&#x2013;110. https://doi.org/10.1136/annrheumdis-2017-211613</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211613</ArticleId><ArticleId IdType="pubmed">28970217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M (2018) Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med 5:e000234. https://doi.org/10.1136/lupus-2017-000234</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000234</ArticleId><ArticleId IdType="pubmed">29531772</ArticleId><ArticleId IdType="pmc">5844382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang ASMW, Bultink IE, Heslinga M, Voskuyl AE (2017) Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatol (Oxford) 56:121&#x2013;128. https://doi.org/10.1093/rheumatology/kew377</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew377</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaoglu H, Li J, Goldman D, Magder LS, Petri M (2020) Time to lupus low disease activity state in the Hopkins Lupus Cohort: role of African American ethnicity. Arthritis Care Res (Hoboken) 72:225&#x2013;232. https://doi.org/10.1002/acr.24063</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24063</ArticleId><ArticleId IdType="pubmed">31507071</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y et al (2016) Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther 18:260. https://doi.org/10.1186/s13075-016-1163-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1163-2</ArticleId><ArticleId IdType="pubmed">27829463</ArticleId><ArticleId IdType="pmc">5103412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SC, Chan EWL, Tang SP (2020) Clinical features, disease activity and outcomes of Malaysian children with paediatric systemic lupus erythematosus: a cohort from a tertiary centre. Lupus 29:1106&#x2013;1114. https://doi.org/10.1177/0961203320939185</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320939185</ArticleId><ArticleId IdType="pubmed">32631203</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelrahman N, Beresford MW, Leone V, U.K. Juvenile-onset SLE, Study Group (2019) Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients. Lupus 28:667&#x2013;674. https://doi.org/10.1177/0961203319840699</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319840699</ArticleId><ArticleId IdType="pubmed">30943853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I, Garantziotis P, Adamichou C, Saridakis I, Spyrou G, Sidiropoulos P et al (2021) High comorbidity burden in patients with SLE: data from the community-based lupus registry of Crete. J Clin Med 10:998. https://doi.org/10.3390/jcm10050998</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10050998</ArticleId><ArticleId IdType="pubmed">33801229</ArticleId><ArticleId IdType="pmc">7957898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosina S, Tibaldi J, Mazzoni M, Bava C, Natoli V, Ravelli A (2020) Update on outcome measures for pediatric systemic lupus erythematosus. Arthritis Care Res (Hoboken) 72(Suppl 10):163&#x2013;170. https://doi.org/10.1002/acr.24212</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24212</ArticleId><ArticleId IdType="pubmed">33091272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G et al (2021) Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus 30:2144&#x2013;2150. https://doi.org/10.1177/09612033211054399</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211054399</ArticleId><ArticleId IdType="pubmed">34723709</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Tharmaratnam K, Al-Abadi E, Armon K, Bailey K, Brennan M et al (2021) Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatol (Oxford). https://doi.org/10.1093/rheumatology/keab915</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677&#x2013;2686. https://doi.org/10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId><ArticleId IdType="pmc">3409311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibanez D, Urowitz MB (2002) Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 29:288&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy DM, Peschken CA, Tucker LB, Chedeville G, Huber AM, Pope JE et al (2013) Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res (Hoboken) 65:152&#x2013;160. https://doi.org/10.1002/acr.21779</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21779</ArticleId><ArticleId IdType="pubmed">22744999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED (2009) Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 36:2539&#x2013;2546. https://doi.org/10.3899/jrheum.081141</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.081141</ArticleId><ArticleId IdType="pubmed">19833755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L (2020) Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatol (Oxford) 59:3622&#x2013;3632. https://doi.org/10.1093/rheumatology/keaa383</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa383</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Hedrich CM (2022) Systemic lupus erythematosus-are children small adults? Z Rheumatol 81:28&#x2013;35. https://doi.org/10.1007/s00393-021-01116-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-021-01116-x</ArticleId><ArticleId IdType="pubmed">34748078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hie M, Pineton de Chambrun M et al (2020) Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 79:339&#x2013;346. https://doi.org/10.1136/annrheumdis-2019-216303</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216303</ArticleId><ArticleId IdType="pubmed">31852672</ArticleId></ArticleIdList></Reference><Reference><Citation>Massias JS, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C et al (2021) Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus 30:597&#x2013;607. https://doi.org/10.1177/0961203320984251</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320984251</ArticleId><ArticleId IdType="pubmed">33413005</ArticleId><ArticleId IdType="pmc">7967896</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinicato NA, Postal M, de Oliveira PK, Rittner L, Marini R, Appenzeller S (2017) Prevalence and features of metabolic syndrome in childhood-onset systemic lupus erythematosus. Clin Rheumatol 36:1527&#x2013;1535. https://doi.org/10.1007/s10067-017-3602-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3602-0</ArticleId><ArticleId IdType="pubmed">28424906</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Song W, Cui D (2022) Relationship between blood lipid profiles and risk of lupus nephritis in children. Int J Clin Pract 2022:6130774. https://doi.org/10.1155/2022/6130774</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/6130774</ArticleId><ArticleId IdType="pubmed">36349053</ArticleId><ArticleId IdType="pmc">9629941</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Davis AM, Klein-Gitelman MS, Cidav Z, Mandell DS, Knight AM (2021) Impact of psychiatric diagnosis and treatment on medication adherence in youth with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 73:30&#x2013;38. https://doi.org/10.1002/acr.24450</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24450</ArticleId><ArticleId IdType="pubmed">32937032</ArticleId></ArticleIdList></Reference><Reference><Citation>AlAhmed O, Sivaraman V, Moore-Clingenpeel M, Ardoin SP, Bout-Tabaku S, investigators Cr, (2020) Autoimmune thyroid diseases, autoimmune hepatitis, celiac disease and type 1 diabetes mellitus in pediatric systemic lupus erythematosus: results from the CARRA Legacy Registry. Lupus 29:1926&#x2013;1936. https://doi.org/10.1177/0961203320961469</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320961469</ArticleId><ArticleId IdType="pubmed">33016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Clarke AE, Zahedi Niaki O, Labrecque J, Schanberg LE, Silverman ED et al (2017) Malignancy in pediatric-onset systemic lupus erythematosus. J Rheumatol 44:1484&#x2013;1486. https://doi.org/10.3899/jrheum.170179</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170179</ArticleId><ArticleId IdType="pubmed">28765255</ArticleId><ArticleId IdType="pmc">5657309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gomez-Puerta JA, Catoggio LJ et al (2019) Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multiethnic, multinational Latin American cohort. J Rheumatol 46:1299&#x2013;1308. https://doi.org/10.3899/jrheum.180433</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180433</ArticleId><ArticleId IdType="pubmed">30824636</ArticleId></ArticleIdList></Reference><Reference><Citation>Poomsalood N, Narongroeknawin P, Chaiamnuay S, Asavatanabodee P, Pakchotanon R (2019) Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus. Lupus 28:1189&#x2013;1196. https://doi.org/10.1177/0961203319862614</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319862614</ArticleId><ArticleId IdType="pubmed">31307256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>